1. In Vivo
  2. >>Innovation

Radiopharmaceuticals: A New Frontier In Precision Cancer Therapy

 
• By Melanie Senior

Growing interest in radioligand-based cancer therapies reflects the class’s unique advantages – including the ability to “see what you treat.”

Torch light
• Source: Shutterstock (Shutterstock)

Targeted radiopharmaceuticals, which combine cancer-seeking ligands with radioactive isotopes to deliver precision radiation, are emerging as a new frontier of cancer care.

That’s the view of the dealmakers and investors driving a flurry of activity in the space: Bristol Myers Squibb Company’s $4.1bn acquisition of RayzeBio and Eli Lilly and...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Innovation

Leaders At The Frontier: Conversations From SynBioBeta 2025

 
• By David Wild

Mini-profiles of five synthetic biology companies and their leaders from SynBioBeta 2025 reveal how AI integration, data-driven platforms and interdisciplinary teams are revolutionizing drug discovery and manufacturing.

From IVF Failure To Fertility Breakthroughs: Freya’s Microbiome Mission

 
• By Jo Shorthouse

Named after the Norse goddess of fertility, Freya Biosciences is mapping the reproductive microbiome with a host of women's health indications as the final destination.

ML-Assisted Genetic Risk Score Predicts GLP-1 Adverse Events

 
• By David Wild

Phenomix Science presented new data at Digestive Disease Week 2025 showing its machine learning-assisted genetic risk score can predict nausea and side effects from GLP-1 receptor agonists, aiding personalized obesity treatment.

The pre|CISION Approach: How Avacta Is Making Toxic Cancer Drugs Safe And More Effective

 
• By Jo Shorthouse

Avacta's approach to drug delivery is showing how 'masked' chemotherapy can dramatically improve safety profiles while maintaining or enhancing efficacy where it matters most.

More from In Vivo